Foundayo results timeline: what to expect, week by week

Last reviewed: 23 August 2026

Weeks 1 to 4: the 0.8 mg introduction

Expect little. This starter dose exists to introduce the medicine gently rather than to drive weight loss, and many people see minimal change on the scales during this month. That is normal and not a sign of failure. What some people do notice is the first quietening of food noise: a slight reduction in snacking, or finishing a meal without finishing the plate.

Side effects, if they arrive, tend to appear in the days after starting. Mild nausea and constipation are the common openers, and our side effects map covers what helps.

Weeks 5 to 12: escalation begins

Through 2.5 mg and into 5.5 mg, appetite suppression usually becomes unmistakable, and steady weight loss typically follows. Each dose increase brings its own short window of gut side effects that generally settles within days to a couple of weeks.³

By around week 12 many people are on the first properly therapeutic dose and have visible progress. Resist the urge to compare your rate against strangers online: starting weight, dose position, diet, activity and biology all differ.

Months 4 to 9: the productive stretch

This is where most of the loss usually accrues, as you climb through 9 mg and potentially beyond. Clothes change before the mirror does, and the scales move unevenly rather than in a neat line: whooshes, flat weeks, and the occasional inexplicable rise are all normal water and digestion noise rather than fat gain. Weigh weekly, at the same time and in the same conditions, and judge the trend line over a month.

It is also the stretch where the habits that decide your long-term outcome get built or missed. Protein, resistance exercise and hydration are doing quiet work here; see our nutrition guide.

Months 10 to 18: the curve flattens

Weight loss slows. This is expected, it happened in the trials too, and it is not the medicine failing. A lighter body burns fewer calories, so the same intake that produced a deficit at the start produces less of one later. The 72-week trial figures are the accumulated total at the end of this whole arc, not a rate that continues indefinitely.²

Plateaus are the single biggest cause of people quitting prematurely. The evidence-based responses are patience, an honest look at whether portions and habits have drifted, and a prescriber conversation about whether there is room left on the dose ladder. What a plateau never justifies is taking extra tablets.

Beyond 18 months: maintenance

At some point the goal shifts from losing to holding, and that phase has its own evidence: ATTAIN-MAINTAIN found people switching from injectable tirzepatide or semaglutide to orforglipron largely maintained their weight loss.² Our maintenance guide covers dosing, reviews and what long-term treatment involves.

What if it is not working for you?

Some people respond less well, and that is a real outcome rather than a personal failing. Before concluding anything, check the obvious: are you actually at a therapeutic dose, or still climbing? Has enough time passed, given the trials measured over 72 weeks? Are diet and activity changes genuinely in place, since the medicine is licensed as an adjunct to them, not a replacement?¹

If the answers are yes and progress has genuinely stalled at a maintained dose, that is the conversation to have with your prescriber. Alternatives exist, including the weekly injections, which showed larger average losses in their own trials: see Foundayo vs Mounjaro.